Zenas BioPharma, Inc. Common Stock (ZBIO NASDAQ) stock market data APIs
$21.8202
-0.2(-0.9%)
as of February 6, 2026
Try our APIs with
free plan!
Zenas BioPharma, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Prev. Close
21.8202
Open
21.6163
High
22.3257
Low
21.0708
52 wk Range
6.11-44.6
Market Cap
1 914 M
P/E Ratio
2.6086
Shares Outstanding
53 679 K
Revenue
15 000 K
EPS
-1.22
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Zenas BioPharma, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Zenas BioPharma, Inc. Common Stock data using free add-ons & libraries
Get Zenas BioPharma, Inc. Common Stock Fundamental Data
Zenas BioPharma, Inc. Common Stock Fundamental data includes:
- Net Revenue: 15 000 K
- EBITDA: -195 616 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.85
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Zenas BioPharma, Inc. Common Stock News
New
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors ar...
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a lead...
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes
Zenas BioPharma Inc. (NASDAQ:ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD). IgG4...
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
Zenas BioPharma ZBIO announced that the phase III INDIGO study, which evaluated its lead pipeline candidate, obexelimab, for treating patients with immunoglobulin G4-related disease (IgG4-RD), has met...
Get Zenas BioPharma, Inc. Common Stock fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
